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BACKGROUND: Obesity is now recognized as the main cause of the worldwide epidemic of type 2 diabetes. Obesity-associated chronic inflammation 
is a contributing key factor for type 2 diabetes and 
cardiovascular disease. Numbers of studies have clearly 
demonstrated that the immune system and metabolism are 
highly integrated.
CONTENT: Macrophages are an essential component of 
innate immunity and play a central role in inflammation 
and host defense. Moreover, these cells have homeostatic 
functions beyond defense, including tissue remodeling 
in ontogenesis and orchestration of metabolic functions. 
Diversity and plasticity are hallmarks of cells of the 
monocyte-macrophage lineage. In response to interferons 
(IFNs), toll-like receptor (TLR), or interleukin (IL)-4/IL-
13 signals, macrophages undergo M1 (classical) or M2 
(alternative) activation. Progress has now been made in 
defining the signaling pathways, transcriptional networks, 
and epigenetic mechanisms underlying M1, M2 or M2-like 
polarized activation.
SUMMARY: In response to various signals, macrophages 
may undergo classical M1 activation (stimulated by TLR 
ligands and IFN-γ) or alternative M2 activation (stimulated 
by IL-4/IL-13); these states mirror the  T helper (Th)1–Th2 
polarization of T cells. Pathology is frequently associated 
with dynamic changes in macrophage activation, with 
classically activated M1 cells implicate in initiating and 
sustaining inflammation, meanwhile  M2 or M2-like 
activated cells associated with resolution or smoldering 
chronic inflammation. Identification of the mechanisms and 
molecules that are associated with macrophage plasticity 
and polarized activation provides a basis for macrophage-
centered diagnostic and therapeutic strategies.
LATAR BELAKANG: Obesitas dikenal sebagai penyebab utama epidemik diabetes tipe 2 di dunia. Inflamasi kronis terkait obesitas adalah faktor 
kunci yang berkontribusi untuk terjadinya diabetes tipe 
2 dan penyakit kardiovaskular. Banyak penelitian telah 
membuktikan adanya integrasi antara sistim imun dan 
metabolisme.
ISI: Makrofag adalah komponen penting pada imunitas 
bawaan dan berperan penting dalam inflamasi dan 
pertahanan inang. Makrofag juga berfungsi untuk menjaga 
homeostasis selain pertahanan tubuh, termasuk remodeling 
jaringan pada ontogenesis dan pengaturan fungsi metabolik. 
Diversitas dan plastisitas merupakan penanda perubahan sel 
dari monosit menjadi makrofag. Sebagai respon terhadap 
sinyal interferon (IFN), toll-like receptor (TLR) atau 
interleukin (IL)-4/IL-13, makrofag menjadi aktif melewati 
aktivasi M1 (klasik) atau M2 (alternatif). Banyak penelitian 
dilakukan untuk mengerti lebih banyak mengenai jalur 
persinyalan, jaringan transkripsi, dan mekanisme epigenetic 
yang mendasari aktifasi polarisasi M1, M2 atau M2-like.
RINGKASAN: Sebagai respons dari berbagai signal 
makrofag dapat teraktivasi melewati M1 klasik (distimulasi 
oleh ligan TLR dan IFN-γ) atau M2 sebagai alternatif 
(distimulasi oleh IL-4/IL-13); hal ini serupa dengan polarisasi 
T helper (Th)1-Th2 pada sel T. Patologi banyak dikaitkan 
dengan perubahan dinamis dalam aktivasi makrofag, 
secara klasik sel dengan M1 teraktivasi menginisiasi dan 
mempertahankan inflamasi, sedangkan sel  dengan M2 
atau M2-like teraktivasi berhubungan dengan timbulnya 
inflamasi kronis. Identifikasi mekanisme dan molekul yang 
terlibat dengan plastisitas dan aktivasi polarisasi makrofag 
menjadi dasar untuk strategi diagnostik dan terapi berbasis 
makrofag.
Abstract Abstrak
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Adipose tissue inflammation is a characteristic of obesity. 
Interactions between metabolic and inflammatory response 
systems play a significant role in the pathogenesis of a cluster 
of chronic metabolic diseases including type 2 diabetes, 
fatty liver disease, and atherosclerosis.(1,2) Macrophage 
infiltration in adipose tissue has recently been described 
in both mice and humans, especially in the later stages of 
obesity.(3,4) It has been suggested that expanding adipocytes 
or neighboring preadipocytes might produce signals leading 
to macrophage recruitment.(5) Alternatively, death of 
adipocytes at late stages of obesity has also been proposed 
as a mechanism of macrophage infiltration into the adipose 
tissue.(6) In fact, this is a very attractive hypothesis since 
much of the presence of macrophages in the adipose tissue 
occurs in a scattered pattern and is found around the dead 
adipocytes in obesity. These observations have raised the 
possibility that macrophages themselves might be a critical 
regulator of metabolism as a result of their inflammatory 
capacity, perhaps independent of their stromal counterparts, 
especially adipocytes. Several studies have identified their 
contributions to the metabolic regulation of pathways that 
act in the macrophage.(7,8)
 Classically activated macrophages (CAMs), termed 
M1, can be induced in vitro by growing bone marrow–derived 
hematopoietic cells with granulocyte macrophage colony 
stimulating factor (GM-CSF). Alternatively, activated 
macrophages (AAMs), termed M2, can be induced by 
culturing the bone marrow–derived cells with macrophage 
colony stimulating factor (M-CSF) and interleukin (IL)-4. 
M1 macrophages secrete a characteristic signature of pro-
inflammatory cytokines, whereas M2 macrophages secrete 
anti-inflammatory cytokines (for example, IL-10 and IL-1 
receptor antagonist (IL-1Ra)).(9)
 in vivo, it is likely that adipose tissue macrophages 
(ATMs) span a spectrum from the M1-like pro-inflammatory 
state to the M2-like non-inflammatory state.(10) Many 
studies have confirmed that the polarization state of an 
ATM correlates well with insulin resistance. For example, 
Fujisaka, et al.(11) showed that the number of M1-like ATMs 
expressing cluster of differentiation (CD)11c correlated with 
insulin sensitivity. The phenotype of ATMs is not fixed, and 
KATA KUNCI: obesitas, jaringan lemak, inflamasi, 
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Introduction they can repolarize from one state to another. For example, evidence suggests that switching from a high fat diet (HFD) 
to a chow diet(12), or treating obese mice with omega-3 
fatty acids(13) or thiazolidinediones (TZDs)(14), can drive 
conversion of the M1 to the M2 type, which is coincident 
with increased insulin sensitivity.
 One can propose that in adipose tissue the recruited 
M1-like CAMs are responsible for the inflammatory 
component of insulin resistance, whereas the resident M2-
like AAMs function in remodeling and tissue homeostasis.
(10)
Inflammation is an adaptive response triggered by noxious 
stimuli and conditions such as infection and tissue 
injury.(15,16) Inflammation underlies a wide variety of 
physiological and pathological processes. Although the 
pathological aspects of many types of inflammation are 
well appreciated, their physiological functions are mostly 
unknown.(17)
 At a basic level, the acute inflammatory response 
triggered by infection or tissue injury involves the 
coordinated delivery of blood components (plasma and 
leukocytes) to the site of infection or injury.(15,16) This 
response has been characterized best for microbial infections 
(particularly bacterial infections), in which it is triggered by 
receptors of the innate immune system, such as Toll-like 
receptors (TLRs) and nucleotide-binding oligomerization 
domain protein (NOD)-like receptors (NLRs).(18) This 
initial recognition of infection is mediated by tissue-resident 
macrophages and mast cells, leading to the production of a 
variety of inflammatory mediators, including chemokines, 
cytokines, vasoactive amines, eicosanoids and products of 
proteolytic cascades.
 A successful acute inflammatory response results 
in the elimination of the infectious agents followed by a 
resolution and repair phase, which is mediated mainly by 
tissue-resident and recruited macrophages.(19) The switch 
in lipid mediators from pro-inflammatory prostaglandins 
to lipoxins, which are anti-inflammatory, is crucial for 
the transition from inflammation to resolution. Lipoxins 
inhibit the recruitment of neutrophils and, instead, promote 
Physiological and Pathological Roles of Inflammation
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the recruitment of monocytes, which remove dead cells 
and initiate tissue remodeling. Resolvins and protectins, 
which constitute another class of lipid mediator, as well as 
transforming growth factor-β (TGF-β) and growth factors 
produced by macrophages, also have a crucial role in the 
resolution of inflammation, including the initiation of tissue 
repair.(19,20) Homeostatic control mechanisms ensure that 
internal environmental parameters (such as glucose and 
oxygen concentrations) are maintained within an acceptable 
range near a certain set point.(21)
 Whatever the cause of the inflammatory response, 
its ‘purpose’ is to remove or sequester the source of the 
disturbance, to allow the host to adapt to the abnormal 
conditions and, ultimately, to restore functionality and 
homeostasis to the tissue. If the abnormal conditions are 
transient, then a successful acute inflammatory response 
returns the system to the basal homeostatic set points. If, 
by contrast, the abnormal conditions are sustained, then an 
ongoing inflammatory state shifts the system to different set 
points, as occurs during chronic inflammation. An adaptive 
change often provides short-term benefits; however, in a 
chronic phase, it can become maladaptive, as exemplified 
by a sustained decline in insulin sensitivity of the skeletal 
muscle or by squamous metaplasia of the respiratory 
epithelium. More specifically, a transient decrease in insulin 
sensitivity during acute inflammation would allow the 
redistribution of glucose from one of its major consumers 
(for example, skeletal muscle) to leukocytes and other cell 
types that can have an increased energy demand during 
infection and tissue repair. However, sustained insulin 
resistance in skeletal muscle can lead to type 2 diabetes.(17)
The mechanisms of systemic chronic inflammatory states 
in general are poorly understood, but it is clear that they do 
not seem to fit the classic pattern of transition from acute to 
chronic inflammation. Thus, in basal conditions, the tissues 
are maintained in a homeostatic state, in many cases with 
the help of the tissue-resident macrophages. In noxious 
conditions, tissues undergo stress and can malfunction. 
If the changes are considerable, then adaptation to the 
conditions requires the help of tissue-resident or recruited 
macrophages and might require small-scale delivery of 
additional leukocytes and plasma proteins, depending 
on the extent of the problem. This adaptive response has 
characteristics that are intermediate between basal and 
inflammatory states. It could be termed para-inflammation 
(para- the Greek prefix for near).
 Indeed, many chronic inflammatory diseases that are 
not caused by infection or injury seem to be associated 
with conditions not present during the early evolution 
of humans, including the continuous availability of high-
calorie nutrients, a low level of physical activity, exposure 
to toxic compounds, and old age. The human diseases that 
are associated with these conditions-including obesity, type 
2 diabetes, atherosclerosis, asthma and neurodegenerative 
diseases are all characterized by chronic low-grade 
inflammation (para-inflammation), which might not have 
any physiological counterparts. Furthermore, the chronic 
para-inflammation that persists in these conditions can 
in turn contribute to further disease progression, in part 
because of changes in homeostatic set points (such as insulin 
sensitivity or blood pressure).(17)
 Thus, tissue stress or malfunction similarly induces 
an adaptive response, which here is referred to para-
inflammation. This response relies mainly on tissue-
resident macrophages and is intermediate between the basal 
homeostatic state and a classic inflammatory response. 
Para-inflammation is probably responsible for the chronic 
inflammatory conditions that are associated with modern 
human diseases.
Approximately 20 years ago, Feingold and Grunfeld 
observed that administration of the proinflammatory 
cytokine tumor necrosis factor-α (TNF-α) led to increased 
serum glucose concentrations, which prompted them to 
suggest that hyperglycemia may be exacerbated by cytokine 
overproduction.(22,23) However, the first studies that 
established the concept of obesity-induced adipose tissue 
inflammation were conducted by Hotamisligil, et al.(24), 
who found that TNF-α was elevated in obese rodents and 
that neutralization of TNF-α ameliorated insulin resistance. 
A mechanistic link between inflammatory processes and 
insulin resistance was further established by the fact that 
the signaling pathways leading to activation of inhibitor of 
κB kinase-β (IKK-β) and nuclear factor-κB (NF-κB) are 
stimulated in obesity and insulin resistance.(25,26)
 Chronic low-grade inflammation induced by 
obesity leads to activation of other protein kinases 
such as Jun N-terminal kinases (JNKs), and ablation 
of JNK in mice fed HFD leads to protection from diet-
induced obesity and inflammation.(8,27,28) Activation 
of inflammatory pathways has since been observed in all 
classical insulin target tissues, including fat(3,4), liver(29) 
and muscle(30,31), indicating that inflammation has a 
broad role in driving the pathogenesis of systemic insulin 
resistance(10). An important finding that helped elucidate 
the cause of tissue inflammation was that adipose tissue 
from obese mice and humans is infiltrated with large 
Metabolism and Immune System
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numbers of macrophages.(3,4) These ATMs can comprise 
up to 40% of the cells in obese adipose tissue.(4) ATMs and 
adipose tissue inflammation have been extensively studied, 
and ATMs have been shown to have a key role in systemic 
insulin resistance, glucose tolerance and the development of 
metabolic syndrome and type 2 diabetes.(32)
 The activation of tissue macrophages triggers the 
release of cytokines, which can induce insulin resistance 
in various ways. Among the proinflammatory cytokines, 
TNF-α is the most studied and has consistently been 
shown to cause insulin resistance. For example, TNF-α 
can stimulate serine kinases—including IKK(33), JNK, S6 
kinase (S6K)(34-36) and mammalian target of rapamycin 
(mTOR)(35), which causes serine phosphorylation of 
insulin receptor substrate-1 (IRS-1), attenuating its ability 
to propagate downstream insulin signaling. IL-1β, which is 
generated by inflammasome activation, can also exert pro-
inflammatory effects(37). The inflammasome is composed 
of NOD-like receptor family, pyrin domain containing 3 
(NLRP3) and the adaptor protein apoptosis–associated 
speck-like protein (ASC) containing a caspase recruitment 
domain. Deletion of NLRP3 or ASC or pharmacological 
inhibition of caspase-1(38) can protect against HFD-
induced insulin resistance and glucose intolerance. Other 
proinflammatory cytokines such as IL-18, C-X-C motif 
chemokine-5 (CXCL5), angiopoietin-related protein 2 and 
lipocalin 2 may contribute to inflammation in the context of 
metabolic disease(9).
 In addition to the pro-inflammatory cytokines, anti-
inflammatory cytokines are elevated in obesity, including 
IL-1Ra(39), secreted frizzled-related protein 5 (SFRP5) and 
IL-10(40). IL-1Ra can block IL-1β signaling, and SFRP5 
inhibits the Wnt pathway by sequestering Wnt proteins 
and preventing them from binding their receptors. IL-
10 can inhibit the deleterious effects of pro-inflammatory 
cytokines on insulin signaling.(41) Furthermore, in vivo 
administration of IL-10 prevents the development of IL-6– 
or lipid-induced insulin resistance(42), and muscle-specific 
transgenic over-expression of IL-10 increases whole-body 
insulin sensitivity(43,44).
 In summary, high expression of pro-inflammatory 
cytokines is associated with insulin resistance, and the 
homeostatic balance between pro- and anti-inflammatory 
cytokines defines the profile and magnitude of inflammation 
and its effects on insulin sensitivity and glucose homeostasis.
 Systemic insulin resistance in obesity can initiate 
largely in adipose tissue, and macrophage-mediated tissue 
inflammation is a core mechanism of this aspect of adipose 
tissue dysfunction. Adipose tissue can communicate with 
the liver and muscle through the release of cytokines, 
adipokines, and fatty acids and possibly through other 
signals that have yet to be identified, thus causing 
effects on systemic inflammation and insulin sensitivity. 
Adipose tissue is often referred to as the master regulator 
in the development of systemic insulin resistance. The 
recognition that inflammatory signaling and metabolic 
signaling are closely linked has given rise to the concept of 
immunometabolism.(10) 
 Thus far, therapeutic strategies that rely on targeting 
single cytokines or receptors (for example, TNF-αand IL-1) 
Figure 1. Immune cells mediate inflammation in adipose tissue.(10) (Adapted with permission from Nature Publishing Group).
 85
Macrophage Polarization in Metabolism and Metabolic Disease (Meiliana A)Indones  Biomed J.  2013; 5(2): 81-90DOI: 10.18585/inabj.v5i2.56
Macrophages have long been considered to be important 
immune effector cells. Élie Metchnikoff, who won the Nobel 
Prize 100 years ago for his description of phagocytosis, 
proposed that the key to immunity was to “stimulate the 
phagocytes”.(50) Since this discovery, immunologists have 
been occupied by the concept of macrophages as immune 
effector cells and by the understanding on how these cells 
participate in host defense. However, by focusing on the 
immune functions of macrophages, immunologists have 
ignored their vital homeostatic roles, which are independent 
of their involvement in immune responses.(51)
 Macrophages are prodigious phagocytic cells that 
clear approximately 2×1011 erythrocytes each day; this 
equates to almost 3 kg of iron and haemoglobin per year that 
is ‘recycled’ for the host to reuse. This clearance process is 
a vital metabolic contribution without which the host would 
not survive. Macrophages are also involved in the removal 
of cellular debris that is generated during tissue remodeling, 
and rapidly and efficiently clear cells that have undergone 
apoptosis. These processes occur independently of immune 
cell signaling, and the removal of ‘effete’ or apoptotic 
cells seems to result in little or no production of immune 
mediators by unstimulated macrophages.(52) Therefore, the 
primary role of macrophages is not to function as an elite 
immune effector cell, but instead as a common ‘janitorial’ 
cell, the main function of which is to clear the interstitial 
environment of extraneous cellular material.(51)
 Macrophages detect the endogenous danger signals 
that are present in the debris of necrotic cells through 
TLRs(52-54), intracellular pattern-recognition receptors 
and the IL-1R, most of which signal through the adaptor 
molecule myeloid differentiation primary-response gene 
88 (MyD88)(53). This function makes macrophages one 
of the primary sensors of danger in the host. The response 
of macrophages to endogenous danger signals is only 
one example of the many different stimuli that trigger 
macrophage activation in tissues. Macrophages have 
remarkable plasticity that allows them to efficiently respond 
to environmental signals and change their phenotype, and 
their physiology can be markedly altered by both innate and 
adaptive immune responses. Thus, macrophages display 
have limited success in humans, suggesting that targeting 
upstream components rather than single cytokines could 
provide a more effective therapeutic approach. A more 
specific approach that selectively targets the proinflammatory 
M1-like, and not the M2-like, macrophages could provide 
therapeutic benefits without inhibiting other innate immune 
functions. A treatment that boosts the number of resident 
M2-like macrophages could also redirect the ATM balance 
to a less proinflammatory state and improve inflammation-
induced insulin resistance.(10)
Heterogeneity of the macrophage lineage has long been 
recognized and, in part, is a result of the specialization of 
tissue macrophages in particular the microenvironments. 
Circulating monocytes give rise to mature macrophages 
and are also heterogeneous themselves, although the 
physiological relevance of this is not yet completely 
understood.(45)
 Peripheral-blood monocytes show morphological 
heterogeneity such as in the variability of size, granularity 
and nuclear morphology. Monocytes are initially identified 
by their expression of large amounts of CD14 (which is 
part of the receptor for lipopolysaccharide). However, 
the subsequent identification of differential expression 
of antigenic markers showed that monocytes in human 
peripheral blood are heterogeneous, and this provided the 
first clues to the differential physiological activities of 
monocyte subsets. Differential expression of CD14 and 
CD16 (also known as Fcγ receptor III (FcγRIII)) allowed 
monocytes to be divided into two subsets: CD14+CD16–
cells, which are often called classic monocytes, because this 
phenotype resembles the original description of monocytes; 
and CD14+ CD16+ cells.(46) It was subsequently shown that 
the CD14+ CD16+ monocytes expressed higher amounts of 
major histocompatibility complex (MHC) class II molecules 
and CD32 (also known as FcγRII), and it was suggested that 
these cells resemble mature tissue macrophages.(47)
 Tissue macrophages have a broad role in the 
maintenance of tissue homeostasis through the clearance 
of senescent cells and the remodeling and repair of tissues 
after inflammation.(48,49) They are generally considered 
to be derived from circulating monocytes and show a high 
degree of heterogeneity. The heterogeneity reflects the 
specialization of function that is adopted by macrophages 
in different anatomical locations. Monocytes migrate from 
the blood into the tissue to replenish long-lived tissue-
specific macrophages of the bone (osteoclasts), alveoli, 
Macrophage Heterogeneity
central nervous system (microglial cells), connective tissue 
(histiocytes), gastrointestinal tract, liver (Kupffer cells), 
spleen and peritoneum.(45) In addition to macrophage 
heterogeneity in different organs, macrophage heterogeneity 
can be observed in a single organ.(45)Macrophage Plasticity andPolarization
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nitric oxide synthase (NOS2), whereas the AAM, by 
contrast, upregulates arginase 1, which produces the 
polyamine precursor urea and ornithine, necessary for 
collagen synthesis and cellular proliferation, respectively.
(60,61) ATMs consist of at least two different phenotypes 
(i.e., classically activated M1 macrophages and alternatively 
activated M2 macrophages). A recent report proposed that 
M1 or M2 ATMs are distinguished by the presence or the 
absence of CD11c, an M1 macrophage marker.(43) M1 
ATMs produce pro-inflammatory cytokines such as TNF-α, 
IL-6, and monocyte chemoattractant protein (MCP)-1, thus 
contributing to the induction of insulin resistance.(45,55,62) 
On the other hand, M2 ATMs, which are the major 
resident macrophages in lean adipose tissue, are reported 
to have a different gene expression profile, characterized 
by the relatively high expression of CD206, arginase-1, 
macrophage galactose N-acetyl-galactosamine specific 
lectin 1 (MglI), and IL-10, which are involved in the repair 
or remodeling of tissues.(11,43,45,55,62,63) Recent studies 
have demonstrated the involvement of M1/M2 ATM in the 
regulation of insulin sensitivity.(11)
 Rather than being a simple inflammatory disease, 
obesity and metabolic syndrome represent derangements in 
macrophage activation with concomitant loss of metabolic 
coordination. As such, the sequelae of obesity are both 
products of the loss of positive macrophage influences 
as well as the presence of deleterious inflammation. The 
Figure 2. Schematic representation of macrophage plasticity and polarization in pathology.(64) (Adapted with permission from 
American Society for Clinical Investigation).
remarkable plasticity and can change their physiology in 
response to environmental cues. These changes can give 
rise to different populations of cells with distinct functions.
 Macrophages are highly heterogeneous hematopoietic 
cells found in nearly every tissue in the body.(45) 
Canonically, these cells have been defined as the sentinels 
of the innate immune system, monitoring the varied tissue 
milieu for early signs of infection or tissue damage. In 
this role, the macrophage is responsible for sensing, 
integrating, and appropriately responding to a bewildering 
array of stimuli from its local microenvironment. Despite 
the daunting array of inputs, macrophage responses are 
coordinated through two distinct and mutually exclusive 
activation programs, termed classical (M1) and alternative 
(M2).(55,56) These activation programs were initially 
defined by their antimicrobial activities: classical activation 
occurs in response to products derived from or associated 
with bacterial infections, such as lipopolysaccharide (LPS) 
and IFNγ, and results in highly inflammatory macrophages 
with high phagocytic and bactericidal potential.(55,57) In 
contrast, alternative activation occurs in response to products 
derived from or associated with parasitic infections, such as 
Schistosoma egg antigen and IL-4 and -13, and promotes 
anti-parasitic functionalities as well as those involved in 
tissue repair and remodeling.(58,59)
 In the CAM, arginine is catabolized to bactericidal 
nitric oxide and citrulline via the induction of inducible 
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The rise in worldwide obesity has resulted in an explosion 
of obesity-related health problems, including insulin 
resistance, type 2 diabetes, coronary artery disease, fatty 
liver disease, and some cancers and degenerative diseases.
(65-67) Since behavioral and dietary approaches have been 
ineffective in combating obesity(68), a greater emphasis is 
being placed on understanding the molecular links between 
obesity and chronic metabolic diseases. In this context, 
chronic, low-grade inflammation, primarily mediated by 
innate and adaptive immune cells, has emerged as a key 
pathogenic link between obesity and its metabolic sequelae 
(1,32,69-72).
 Obesity-associated insulin resistance, diabetes, and 
metabolic syndrome are sustained by chronic subclinical 
inflammation.(1) ATMs are a major component of adipose 
tissue and have an important role in the obesity-associated 
pathology.(64) ATMs from obese mice and humans are 
polarized toward an M1 phenotype, with upregulation of 
TNF and iNOS. In contrast, “lean” ATMs express high levels 
of M2 genes, including IL-10, Ym1, and Arginase 1.(43,73) 
Weight loss is associated with a back shift to an M2-like 
phenotype. However, evidence indicated that the ATM 
population in obese patients is diverse, with a minor F4/80+ 
CD11b+ CD11c–, IL-10+, M2-like population co-existing 
with M1 cells.(73) Moreover, analysis of CD11c+ ATMs 
from obese mice revealed a mixed profile of several M1-
M2 gene  transcripts.(74)  Weight loss is associated with an 
increase in F4/80+ CD11c– CD301+ M2-like macrophages, 
which promote lipolysis.(75)
 Progress has been made in defining the molecular 
pathways that account for polarization of ATMs in obesity.
(59,76-79) Mice with macrophage-selective genetic 
inactivation of (PPAR)γ,  PPARδ,  and  Klf4  show  inhibition 
of  obesity-induced  insulin  resistance.(59,73,76-78) 
Molecular determinants of M1 versus M2 polarization 
include members of the PPAR, Klf, IRF, STAT, NF-κB, and 
HIF families. Regulation of skewing also involves epigenetic 
modifications with involvement of histone methylation 
and acetylation. miRNAs have emerged as regulators of 
phagocyte activation and function(80,81), but their role 
in macrophage polarization needs to be  further defined. 
Nguyen, et al. have recently demonstrated that adaptation 
to lower temperatures (thermogenesis) is associated with 
polarization of brown adipose tissue (BAT) and white 
adipose tissue (WAT) macrophages to the alternative 
state  (M2), with increased expression of thermogenic 
genes (PPARγc1  and uncoupling protein 1 (Ucp1)).(82) 
In response to cold, IL-4–driven M2 macrophages release 
noradrenaline in BAT and WAT, which coordinates fatty 
acid mobilization and energy expenditure.(82)
 M2-like cells in non-obese individuals are likely 
involved in maintaining adipose tissue homeostasis, 
preventing inflammation, and promoting insulin sensitivity. 
The role of macrophages in obesity and associated disorders 
underlines a homeostatic function of macrophages 
in metabolism as cells  capable of reorienting their 
own metabolic activity and as orchestrators of general 
metabolism.(64)
 The wealth of literature on macrophages and other 
leukocytes in adipose tissue clearly defines functional roles 
for these cells in adipose tissue biology and establishes them 
as bonafide tissue constituents rather than immunologic 
transients. The physiologically normal set points in fat 
tissue can be shifted by chronic over-nutrition; the pro-
inflammatory obese adipose tissue itself, once established, 
demonstrates temporal stability and resistance to change. 
As in lean adipose tissue, any perturbation of leukocyte set 
points, whether numeric or phenotypic, disrupts the tissue’s 
new functional parameters.(83)
 Therapeutic macrophage targeting is in its infancy. 
Selected clinically approved therapeutic strategies, such 
as use of PPARγ inhibitors, statins, zolendronic acid, and 
preventive activities such as weight loss may have an 
impact on the functional status of macrophages; however, 
the extent to which their effect on macrophages explains 
their clinical efficacy remains to be defined.(64) The 
identification of mechanisms and molecules associated with 
macrophage plasticity and polarized activation provides a 
basis for macrophage-centered diagnostic and therapeutic 
strategies.
Metabolic function requires a previously unsuspected level 
of cooperation between the cells that make up each internal 
organ and that organ’s resident macrophages. Disruption 
in the tissue set point results in significant functional 
consequences for both the tissue and the organism as a 
whole. If nutrient intake and expenditure are mismatched 
over a long period of time, however, a new set point is 
Macrophage Polarization and Metabolic Disease
Conclusion
therapeutic implications of this conclusion are profound 
because they suggest that pharmacologic targeting of 
macrophage activation, rather than purely inflammation, 
might be efficacious in treating this global epidemic.(59)
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